IRB #

IRB00007561

Title

C80702: A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Principal Investigator

Gina Vaccaro

Study Purpose

The primary objective of this study is to compare disease-free survival of subjects with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib (the study drug) daily.

Medical Condition(s)

Colon

Eligibility Criteria

* Colon Cancer
* Must have had tumor surgically removed
* No evidence of metastatic disease
* Cant be using NSAIDs regularly, or aspirin more than 100mg a day.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Up to 6 years.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

CALGB

Recruitment End

Compensation Provided

No